- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04063644
Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients
Effect of Visglyc on the Quality of Life of Patients With Dry Eye Symptomatology and Age-related Loss of Visual Acuity
Clinical trial with medical devices, post-authorization, parallel, single-blind, randomized, comparative, prospective to study how afects the quality of life the use of ocular eye drops on patients with dry eye symptomatology and age-related loss of visual acuity.
Secondary purposes: efects on the dry eye symptomatology, efect on visual acuity and treatment adherence.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects between the ages of 50 and 70.
- Subjects with initial or slight changes characteristic of cataracts (grade 1-3 according to LOCS III classification).
- Subjects with dry eye symptoms.
- Confirmation of senile cataract diagnosis according to medical history and clinical observations, bilateral.
- Visual acuity equal to or greater than (0.6) in both eyes (with the best correction).
- Cataracts without the need for surgical intervention in the near future (1 year) based on the visual needs of the patient and ocular symptomatology.
- Subjects that have not undergone cataract surgery.
- Cases that do not accept surgery (weak corneas, high degree of myopia, sensitivity to light, severe dryness of the eyes or by their own decision).
- Subjects who agree to sign the IC (Informed Consent).
Exclusion Criteria:
- Subjects with eye diseases such as glaucoma or diabetic retinopathy.
- Previous laser photocoagulation of the retina.
- Previous corneal or anterior segment surgery or previous corneal scars that may interfere with visualization or photographs.
- Presence of mature cataracts (grade 4-5/6 according to LOCS III classification) in both eyes.
- Candidates for surgery in the following year.
- Subjects with monocular aphakia (absence of crystalline lens) or secondary cataracts (associated with steroid use, local or total irradiation, local inflammation or degenerative processes, ocular trauma).
- Subjects with known hypersensitivity to any component of ophthalmic treatment.
- Subjects treated with drugs that may interfere with the evolution of the disease under study.
- Subjects who wear contact lenses.
- Pregnant women.
- Breastfeeding women.
- Subjects who have participated in another clinical trial within the last 30 days.
- Subjects with linguistic or psychological incapacity to understand and sign the CI.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vis Glyc Neo
Vis glyc eye drops is administered. Eye drops based on N-Acetylcoarnosine, Vaccinium myrtillus and Chondroitin sulfate |
1 drop in each eye, three times a day.
|
Active Comparator: physiological saline solution
Physiological saline solution ALVITA is administered.
|
1 drop in each eye, three times a day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in quality of visual life: NEI VFQ-25 questionnaire
Time Frame: Change from baseline quality of life at 6 months
|
In patients with dry eye symptomatology and age-related loss of visual acuity. Assessed using NEI VFQ-25 questionnaire. It is a questionnaire with 25 questions. Its format is divided into 4 subscales: visual function, difficulty with activities, driving a car and responding to vision problems. It consists of a base of 25 questions (each with five or six levels of response and scoring ranges) addressed to vision, representing 11 domains, elements or items related to health; 1) general vision, 2) eye pain, 3) near activities, 4) distance activities, 5) social functioning, 6) mental health, 7) role difficulties or limitations, 8) dependence, 9) driving, 10) color vision and 11) peripheral vision. Each domain receives an evaluation from 0 to 100; the high evaluation represents changes in visual functioning, where 0 is the lowest and 100 is the best possible. |
Change from baseline quality of life at 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in quality of visual life: NEI VFQ-25 questionnaire
Time Frame: 0, 30, 90, 180 days
|
In patients with dry eye symptomatology and age-related loss of visual acuity. Assessed using NEI VFQ-25 questionnaire. It is a questionnaire with 25 questions. Its format is divided into 4 subscales: visual function, difficulty with activities, driving a car and responding to vision problems. It consists of a base of 25 questions (each with five or six levels of response and scoring ranges) addressed to vision, representing 11 domains, elements or items related to health; 1) general vision, 2) eye pain, 3) near activities, 4) distance activities, 5) social functioning, 6) mental health, 7) role difficulties or limitations, 8) dependence, 9) driving, 10) color vision and 11) peripheral vision. Each domain receives an evaluation from 0 to 100; the high evaluation represents changes in visual functioning, where 0 is the lowest and 100 is the best possible. |
0, 30, 90, 180 days
|
Visual Acuity Evaluation I
Time Frame: 0, 90, 180 days
|
To assess the age-related visual acuity in patients. - The CSV-1000E contrast sensitivity test. This test provides for four (4) rows of sine-wave gratings. These gratings test the spatial frequencies of 3, 6, 12 and 18 cycles/degree (CPD). The levels of contrast are 1 to 8. The higher the contrast or modulation, the greater the difference in luminance and the better the object will be distinguished from the background. |
0, 90, 180 days
|
Visual Acuity Evaluation II
Time Frame: 0, 90, 180 days
|
To assess the age-related visual acuity in patients. - LOCS III classification of cataract grade using images obtained by ophthalmoscopy with slit lamp, which allows the study of the anterior segment of the patient's eye. It consists of six slit lamp images to evaluate core color (NC) and opalescence (NO); five backlit images to evaluate cortical cataract (C); and five backlit images to evaluate posterior subcapsular cataract (P). The severity of the cataract is classified on a decimal scale, and the patterns have regularly separated intervals on a decimal scale. |
0, 90, 180 days
|
Visual Acuity Evaluation III
Time Frame: 0, 90, 180 days
|
To assess the age-related visual acuity in patients. - Visual acuity test with the best correction in each eye using Snellen E-screens, measured in decimal system and MAR logarithm. Level of vision with respect to the row in Snellen's graph, which the rows consist of 1 to 11. The lower the row (greater numbers) the patient can distinguish, the greater the visual acuity he will have. |
0, 90, 180 days
|
Dry eye symptomatology Evaluation I
Time Frame: 0, 90, 180 days
|
Schirmer I test (without anesthesia): to determine the dryness of the eye.
It consists of placing a thin strip of paper at the bottom of the conjunctival sac and before this foreign body see the patient's tear production capacity (measuring the wet area in mm).
The less mm the less tear production capacity.
|
0, 90, 180 days
|
Dry eye symptomatology Evaluation II
Time Frame: 0, 90, 180 days
|
- Fluorescein staining test: to assess dryness of the eye.
Fluorescein is instilled in both conjunctival sacs.
Absence of staining indicates integrity of the corneal epithelium.
There are degrees of fluorescein staining from 0 to 5. The highest the worst results.
|
0, 90, 180 days
|
Dry eye symptomatology Evaluation III
Time Frame: 0 and 180 days
|
The OSDI Test (ocular surface disease index) is a simple test created to establish the severity and classification of dry eye according to its symptoms. It is based on 12 different questions about situations related to patient symptomatology. A score of 100 corresponds to a total disability (answer "At all times" to all questions answered), while a score of 0 corresponds to no disability. |
0 and 180 days
|
Treatment adherence
Time Frame: 30, 90 and 180 days
|
Ask patients about the daily administration of the treatment according to the protocol.
|
30, 90 and 180 days
|
Adverse events
Time Frame: 30, 90 and 180 days
|
Number of participants with Adverse events and types of adverse events.
|
30, 90 and 180 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Beatriz Sarmiento Torres, MD, MSc, Hospital Universitario 12 Octubre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPK-GLY-2018-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataract
-
Fundación Pública Andaluza para la Investigación...CompletedCataract | Cataract Mature | Cataract, Nuclear
-
Johannes Kepler University of LinzCompletedCataract Complicated | Cataract Complications OperationsAustria
-
Gemini Eye ClinicRecruitingBilateral Cataract | Unilateral CataractCzechia
-
Universitaire Ziekenhuizen KU LeuvenLaboratoires TheaRecruiting
-
Omer Othman AbdullahCompletedCongenital Cataract | Pediatric CataractIraq
-
Johannes Kepler University of LinzRecruitingAphakia | Secondary Cataract Surgery | Complicated Cataract SurgeryAustria
-
Yonsei UniversityCompletedCataract PatientsKorea, Republic of
-
Advanced Center for Eyecare GlobalNot yet recruiting
-
Vienna Institute for Research in Ocular SurgeryRecruiting
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityNot yet recruitingCataract ExtractionChina
Clinical Trials on Vis Glyc Neo
-
TR TherapeuticsCompleted
-
Aboca Spa Societa' AgricolaLatis S.r.l.; Fondazione Edmund MachCompleted
-
University Hospital, GhentUniversity GhentNot yet recruiting
-
TR TherapeuticsCompleted
-
Riphah International UniversityCompletedAutism Spectrum DisorderPakistan
-
Dr Kundan Singh ChufalActive, not recruitingEsophageal NeoplasmAustralia, India
-
Neuracle Medical Technology(Shanghai) Co.,Ltd.Beijing Tiantan Hospital; Chinese PLA General Hospital; Xuanwu Hospital, BeijingNot yet recruiting
-
Gentuity, LLCRecruiting
-
Gentuity, LLCCompleted